Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Ipsen Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults Canada NewsWire MISSISSAUGA, ON, March 15, 2018 With this approval, DYSPORT THERAPEUTIC now has the broadest label of all approved...
Regulatory News: Ipsen (Euronext:IPN; ADR:IPSEY) today announced that lanreotide (Somatuline ® ), cabozantinib (Cabometyx ® ), and telotristat ethyl (Xermelo ® ), alongside research on real-world NET treatment, nuclear medicine and imaging, and the patient experience will ...
Regulatory News: Arix Bioscience plc (LSE:ARIX) (“Arix”), a global healthcare and life science company supporting medical innovation, and Ipsen (Euronext: IPN; ADR:IPSEY), a global specialty-driven biopharmaceutical company focused on innovation and specialty care, tod...
Ipsen S.A. ADR (IPSEY) Q4 2017 Earnings Conference Call February 15, 2018 8:30 AM ET Executives David Meek - Chief Executive Officer Aymeric Le Chatelier - Chief Financial Officer Analysts Jean-Jacques Le Fur - Natixis Matt Weston - Credit Suisse Sachin Jain - Bank of Ame...
Oral Presentations at the 2018 Annual Meeting of the Association of Academic Physiatrists (AAP) Provide Additional Data on the Safety and Efficacy of Dysport ® in Adults with Upper and Lower Limb Spasticity and Children with Lower Limb Spasticity Ipsen Biopharmaceutica...
The following slide deck was published by Ipsen S.A. ADR in conjunction with their 2017 Q4 earnings Read more ...
Ipsen S.A. ADR ( OTCPK:IPSEY ): FY EPS of €4.36 More news on: Ipsen S.A. ADR, Ipsen S.A., Earnings news and commentary, Healthcare stocks news, Read more ...
Regulatory News: Ipsen (Euronext:IPN; ADR:IPSEY), a global specialty-driven biopharmaceutical group, today announced financial results for the full year 2017. Financial highlights Full Year 2017 Group sales growth of 21.1% 1 driven by Specialty Care sales growth of 25.9% 1 ...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that results from its Neurosciences portfolio are the subject of eight oral presentations at the World Congress for Neurorehabilitation (WCNR 2018). The presentations focus on improvements in care for patients with spasti...
The following slide deck was published by Ipsen S.A. ADR in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...